BMS won the nullity trial for the Baraclude’s patent
BMS Pharmaceutical Korea announced on the 13th that it won a nullity trial for the substance patent of the hepatitis type B treatment ‘Baraclude (generic name: entecavir)’.
Eun-young Kim, CEO of BMS Pharmaceutical Korea, stated “We welcome the reasonable decision of the patent judge who againcla...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
